AACR: Chinese Pharma Firms Showcase Enhertu Fast-Followers
Potential Efficacy, Safety Benefits?
Executive Summary
Three Chinese companies including Hengrui Medicine are trying to overtake AstraZeneca and Daiichi Sankyo with their me-too rivals to Enhertu in the sizzling field of HER2-targeting antibody-drug conjugates.
You may also be interested in...
Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss
The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co’s Prometheus deal; Lilly’s US mirikizumab rejection; Moderna and Merck’s mRNA cancer vaccine shows promise; how SeaGen nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.